Research

Physicians in the University of Maryland Medical Center's Inflammatory Bowel Disease (IBD) Program are actively involved in clinical research. For more information about current clinical trials or past publications, please click on the links below.

Clinical Trials

The UMB IBD program is a member of the Clinical Research Alliance of the Crohn's and Colitis Foundation of America. Currently, the UM IBD program offers the following clinical research studies for patients to participate in:

  1. TELEmedicine in Patients with Inflammatory Bowel Disease: TELE-IBD

    The goals of this study are evaluate the impact of a home telemedicine system for patients with inflammatory bowel disease on disease activity, quality of life, and utilization of health care resources compared to best available care.

    For further information, please click here or call the principal investigator Raymond Cross, M.D., M.S., at 410-706-3387.

  2. CTRC-Randomized Double Blind Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid-Free Remission in Ulcerative Colitis.

    For further information, please click here or call the principal investigator Mark Flasar, M.D., M.S., at 410-706-3387.

  3. Gene Discoveries in Subjects with Crohn's Disease of African Descent

    For more information, please call the principal investigator Raymond Cross, M.D., M.S., at 410-706-3387.

  4. 611: A Multicenter, open-label study to evaluate the safety of PROCHYMAL® (remestemcel-L) intravenous infusion in subjects who have received previous remestemcel-L induction treatment for treatment-refractory moderate-to-severe Crohn’s disease.

    For further information, please click here or call the principal investigator Raymond Cross, M.D., M.S., at 410-706-3387.

  5. 603: A Phase III, multicenter, placebo-controlled, randomized, double-blind study to evaluate the safety and efficacy of PROCHYMAL® (ex vivo cultured adult human mesenchymal stem cells)) intravenous infusion for the induction of remission in subjects experiencing treatment-refractory moderate-to-severe Crohn’s disease.

    For more information, please click here or call the principal investigator Raymond Cross, M.D., M.S., at 410-706-3387.

  6. A Prospective Multicenter Trial Evaluating the Benefit of Initial Surgically Established Drainage Prior to Medical Therapy for the Treatment for Crohn's Perianal Fistulas

    For more information, please click here, or call the principal investigator Leyla Ghazi, M.D., at 410-706-3387.

  7. A 5-Year, Registry Study of Humira (Adalimumab) in Patients with Moderately to Severely Active Crohn's Disease (CD)

    For more information, please click here, or call the principal investigator Mark Flasar, M.D., M.D., at 410-706-3397.

  8. INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

    For more information, please click here, or call the principal investigator Raymond Cross, M.D., M.S., at 410-706-3387.

  9. SECURE: A Non-Interventional Long-term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia) for Crohn's Disease

    For more information, please click here, or call the principal investigator Mark Flasar, M.D., M.S., at 410-706-3387.

We are also actively involved in a number of other research projects, including but not limited to:

  • Disparities in Treatment in Patients with Inflammatory Bowel Disease
  • Racial Differences in Disease Activity and Quality of Life in Patients with Inflammatory Bowel Disease
  • Do Anti-TNF agents increase the risk of complications after abdominal surgery?
  • Are Anti-TNF Agents Radiation-Sparing in Patients with Crohn's Disease?
  • What are the Risk Factors for Progression to Complicated Crohn's disease and Disability?
  • Differences in Serologic Expression to Microbial Antigens between Young and Older Patients with Crohn's Disease
  • What are the risk factors for vitamin D deficiency and impact of replacement on disease activity and quality of life in Inflmmatory Bowel Disease?
  • What is the prevalence of sexual dysfunction and distorted body image in patients with Inflammatory Bowel Disease?
  • What is the impact of medical treatment on sexual function and body image in Inflammatory Bowel Disease?
  • What are the risk factors for chronic narcotic use in patients with Inflammatory Bowel Disease?
  • What is the accuracy of magnetic resonance imaging compared to operative and endoscopic findings in patients with Crohn's disease?
  • Does fecal bacterial populations correlated with complicated Crohn's disease and recurrence after surgery?

top


Publications

  1. Cross RK, Wilson KT, Binion DG. Polypharmacy and Crohn's disease. Aliment Pharmacol Ther 2005;21:1211-6
  2. Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol 2005;100(10):2225-9.
  3. Cross RK, Arora M, Finkelstein J. Acceptance of telemanagement is high in patients with inflammatory bowel disease. J Clin Gastroenterol 2006;40(3):200-8.
  4. Cross RK, Jung C, Wasan S, Joshi G, Sawyer R, Roghmann MC. Racial Differences in Disease Phenotypes in Patients With Crohn's Disease. Inflamm Bowel Dis 2006;12(3):192-198.
  5. Castro, HK, Cross, RK, and Finkelstein, J. Using a Home Automated Telemanagement System (HAT): Experiences and Perceptions in Patients with Inflammatory Bowel Disease. AMIA Annu Symp Proc 2006; 872.
  6. Cross, RK, and Finkelstein, J. Feasibility and Acceptance of a Home Telemanagement System in Patients with Inflammatory Bowel Disease: A 6-Month Pilot Study. Dig Dis Sci 2007;52(2):357-364
  7. Donovan, M, Lunney, K, Carter-Pokras, O, and Cross, RK. Prescribing Patterns and Awareness of Adverse Effects of Infliximab: A Health Survey of Gastroenterologists. Dig Dis Sci. Aug 2007;52(8):1798-1805. Dunnigan, M, Yfantis, H, Rapoport, AP, Hosseinzadeh, K, Gocke, CD, and Cross, RK. Large cell lymphoma presenting as a flare of colitis in a patient with common variable immune deficiency. Dig Dis Sci. 2007;52(3):830-4.
  8. Cross, RK, Lapshin, O, and Finkelstein, J. Patient Subjective Assessment of Drug Side Effects in Inflammatory Bowel Disease. J Clin Gastroenterol. 2008;42(3):244-51
  9. Flasar MH, Johnson T, Roghmann MC, Cross RK. Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: A retrospective cohort study. Inflamm Bowel Dis. 2008;14(1):13-9
  10. Flasar, M, Quezada, S, Bijpuria, P, Wu, Roger, and Cross, RK. Racial Differences in Extent, Severity, and Extraintestinal Manifestations in Patients with Ulcerative Colitis: A Retrospective Cohort Study. Dig Dis Sci. 2008; 53(10), 2754-2760
  11. Greenberg, R, Greenwald, B, Ioffe, O, Roth, S, and Cross, RK. Squamous Dysplasia of the Rectum in a Patient with Ulcerative Colitis Treated with 6-Mercaptopurine. Dig Dis Sci. 2008;53(3):760-4.
  12. Quezada, S, Turner, P, Alexiev, B, Daly, B, and Cross, RK. “Severe Refractory Orofacial Crohn’s Disease: Report of a Case”. Dig Dis Sci 2009;54(10):2290-5.
  13. Cross RK, Cheevers N, Finkelstein J. Home Telemanagement for Patients with Ulcerative Colitis (UC HAT). Dig Dis Sci 2009;54(11):2463-2472.
  14. St. Charles, M, Weiss Smith, SR, Beardsley, R, Fedder, DO, Carter-Pokras, O, and Cross, RK. Gastroenterologists Prescribing of Infliximab: A National Survey. Inflamm Bowel Dis. 2009; 15(10)1467-75
  15. Cross R, Finkelstein J. Challenges in the design of a Home Telemanagement Trial for patients with ulcerative colitis. Clin Trials 2009;6(6) 649-57.
  16. Ghazi, L and Cross, RK. Fever of Unknown Origin in an Immune Suppressed Patient with Crohn’s Disease: An Unusual Cause. Practical Gastroenterology 2010:34(11) 42-46.
  17. Samimi, R, Flasar, MH, Kavic, S, Tracy, K, and Cross, RK. Outcome of Medical Treatment of Stricturing and Penetrating Crohn’s Disease: A Retrospective Study. Inflamm Bowel Dis. 2010; 16(7)1187-1194.
  18. Cross, RK, Cheevers, N, Rustgi, A, Langenberg, P, and Finkelstein, J. A Randomized, Controlled Trial of Home Telemanagement in Patients with Ulcerative Colitis (UC HAT). Inflamm Bowel Dis 2012;18(6) 1018-1025.
  19. Cross, RK. Application of Telemedicine for Inflammatory Bowel Disease: Review of the Literature and Future Implications. J Gastrointest Digest Sys. October 2011:1(e102).
  20. Flasar, MH, Cross, RK, and Doman, DB. Current and Future Role of Ulcerative Colitis Serogenomics. Gastroenterology and Hepatology. November 2011:7(11) 720-727.
  21. Patil, SA, Rustgi, A, Quezada, SM, Flasar, MH, Vandermeer, F, and Cross RK. Anti-TNF Therapy is Associated with Decreased Imaging and Radiation Exposure in Patients with Crohn’s Disease. Inflamm Bowel Dis. 2012.
  22. Quezada, SM and Cross, RK. Association of Age at Diagnosis and Ulcerative Colitis Phenotype. Dig Dis Sci. 2012:57(9) 2402-2407.
  23. Faust, AH, Halpern, LF, Danoff-Burg, S, and Cross, RK. Psychosocial Factors Contributing to Inflammatory Bowel Disease Activity and Health-Related Quality of Life. Gastroenterology & Hepatology. March 2012:8(3) 1-9.
  24. McLean, LP, Shea-Donahue, T, and Cross, RK. Vedolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease. Immunotherapy. 2012: 4(9) 883-898.
  25. Quezada, SM, Steinberger, EK, and Cross, RK. Association of Age at Diagnosis and Crohn’s Disease Phenotype. Age Ageing. August 2012: 0:1-4..
  26. Patil, SA, Rustgi, A, Langenberg, P, and Cross, RK. Comparative Effectiveness of Anti-TNF Agents for Crohn’s Disease in a Tertiary Referral IBD Practice. Dig Dis Sci. 2012.
  27. Ghazi, LJ, Patil, SA, Rustgi, A, Flasar, MH, Razeghi, S, and Cross, RK. Step Up versus Early Biologic Therapy for Crohn’s Disease in Clinical Practice. Inflamm Bowel Dis. In press.
  28. Syed, A, Cross, RK, and Flasar, MH. Anti-Tumor Necrosis Factor Therapy is Associated with Infections after Abdominal Surgery in Crohn’s Disease Patients. Am J Gastroenterol. In press.

top

For more information about our services or treatment options or to refer a patient to the IBD Program, please call 410-706-3387.

This page was last updated: April 23, 2013

         
Average rating (0)